GE HealthCare (Nasdaq: GEHC), a pioneer in breast health technology and diagnostics, will unveil its newest breast cancer detection advancements at the 2024 Society of Breast Imaging Symposium in Montreal, Canada, from April 11-14, 2024. The showcase will spotlight the Mobile Mammography Screening Truck, the newly launched MyBreastAI Suite*, and the Pristina Bright** offering, highlighting the company’s commitment to personalized breast cancer imaging solutions.
Breast cancer, affecting one in eight women, demands vigilant screening. GE HealthCare introduces innovative solutions to enhance detection and diagnosis, particularly for women with dense breast tissue, who face increased cancer risk.
GE HealthCare’s MyBreastAI Suite integrates advanced AI applications from iCAD, including ProFound AI for DBT, SecondLook for 2D Mammography, and PowerLook Density Assessment. These tools aid in early detection and workflow efficiency.
Pioneering Contrast-Enhanced Mammography (CEM) technology, GE HealthCare offers Pristina Bright, a comprehensive solution combining SenoBright HD and Pristina Serena. Pristina Bright enables rapid lesion visualization and biopsy, supporting efficient diagnosis and patient care.
Dr. Jordana Phillips from Boston Medical Center attests to CEM’s efficacy in improving breast cancer outcomes, emphasizing its ability to provide additional diagnostic information.
Attendees at SBI 2024 will experience GE HealthCare’s mobile mammography showcase, featuring Senographe Pristina and Invenia ABUS systems, facilitating convenient and accurate screenings.
GE HealthCare’s booth at SBI 2024 will feature personalized breast cancer screening solutions, including Senographe Pristina, Invenia ABUS, SenoBright HD CEM, and Serena Bright contrast-guided biopsy.
About GE HealthCare Technologies Inc.: GE HealthCare is a global leader in medical technology and digital solutions, dedicated to enhancing patient care through innovation and integration across the care pathway. With a legacy of over 125 years, GE HealthCare remains committed to advancing personalized, connected, and compassionate care.
